News Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010 February 2, 2023 By Ellen Leventry This article is sourced from an external publication. Read the original → ← PreviousOligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative DiseasesNext →Oligomerix Publishes Preclinical Data on Novel Small Molecule Therapeutic in Development for Alzheimer’s Disease and Rare Neurodegenerative Diseases
